Delisting risk
Lite Strategy (LITS)
Manages a Litecoin reserve strategy while retaining two pre-clinical oncology drug assets.
$1.01
Pre-market−0.03 (−3.35%)
At close$1.05(+5.13%)
Something off on this page? Send us feedback.
Next report
Sep 28, 2026
estimated · in 25 days
EPS estimate
−$3.12
Revenue estimate
$5.4M
Fiscal quarter
Q4 FY26
EPSReportedEstimate
Sep '24Dec '24May '25Sep '25Nov '25Feb '26May '26Sep '26
Reported−$1.20−$0.40−$0.39−$0.40−$0.12−$0.82−$0.66Pending
Estimate−$1.70−$2.20————−$3.12−$3.12
Surprise+29.3%+81.7%————+78.8%—
RevenueReportedEstimate
Sep '24Dec '24May '25Sep '25Nov '25Feb '26May '26Sep '26
Reported———————Pending
Estimate——————$5.4M$5.4M
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$3.12 | — | — |
| May 2026 | −$3.12 | −$0.66 | +78.8% |
| Feb 2026 | — | −$0.82 | — |
| Nov 2025 | — | −$0.12 | — |
| Sep 2025 | — | −$0.40 | — |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||
| May 2025 | |||
| Dec 2024 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Nov 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | −$3.12 | — | — | $5.4M | — | — | — |
| May 13, 2026 | −$3.12 | −$0.66 | +78.8% | $5.4M | — | — | +3.4% |
| Feb 17, 2026 | — | −$0.82 | — | — | — | — | 0.0% |
| Nov 14, 2025 | — | −$0.12 | — | — | — | — | −5.9% |
| Sep 29, 2025 | — | −$0.40 | — | — | — | — | −4.7% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||||||
| May 13, 2025 | |||||||
| Dec 31, 2024 | |||||||
| Sep 30, 2024 | |||||||
| Jun 30, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Nov 9, 2023 | |||||||